Science Lessons : What the Business of Biotech Taught Me About Management
Book Details
Format
Hardback or Cased Book
ISBN-10
1591398614
ISBN-13
9781591398615
Publisher
Harvard Business Review Press
Imprint
Harvard Business Review Press
Country of Manufacture
GB
Country of Publication
GB
Publication Date
Mar 18th, 2008
Print length
304 Pages
Weight
488 grams
Dimensions
21.50 x 14.30 x 2.60 cms
Product Classification:
Chemical industriesBiotechnology
Ksh 5,400.00
Werezi Extended Catalogue
Delivery in 28 days
Delivery Location
Delivery fee: Select location
Delivery in 28 days
Secure
Quality
Fast
Widely regarded as an innovative, successful biotech firm, Amgen led its industry in revenue and sales growth in 2007. This book reveals the highs and lows it experienced in the race to develop drugs. It takes readers from the time Amgen had just three months of capital in the bank and no viable products in the pipeline to its success.
Widely regarded as the most innovative, successful biotech firm ever, Amgen led its industry in revenue and sales growth in 2007. Top magazines including Fortune and Industry Week have repeatedly named it one of America''s best companies to work for.
In Science Lessons, Gordon Binder—CEO and chairman during 1988-2000—describes Amgen''s climb to success. Revealing the highs and lows it experienced in the race to develop blockbuster drugs, he takes readers from the time Amgen had just three months of capital in the bank and no viable products in the pipeline to its spectacular success. The turning point? The 1989 launch of Epogen, which dramatically helped kidney dialysis patients suffering from debilitating anemia. Other landmark drugs, including Neupogen, would follow.
Through engaging anecdotes and cogent insights, Binder weaves a fascinating tale while offering his unique brand of practical management advice. Using the principals of the scientific method, he shares his recommendations for tackling pressing business challenges—such as managing creative employees, navigating the IPO process, and protecting intellectual property.
This colorful first-person account showcases the visionary science and daring business strategy that made Amgen great—offering valuable lessons for all companies.
In Science Lessons, Gordon Binder—CEO and chairman during 1988-2000—describes Amgen''s climb to success. Revealing the highs and lows it experienced in the race to develop blockbuster drugs, he takes readers from the time Amgen had just three months of capital in the bank and no viable products in the pipeline to its spectacular success. The turning point? The 1989 launch of Epogen, which dramatically helped kidney dialysis patients suffering from debilitating anemia. Other landmark drugs, including Neupogen, would follow.
Through engaging anecdotes and cogent insights, Binder weaves a fascinating tale while offering his unique brand of practical management advice. Using the principals of the scientific method, he shares his recommendations for tackling pressing business challenges—such as managing creative employees, navigating the IPO process, and protecting intellectual property.
This colorful first-person account showcases the visionary science and daring business strategy that made Amgen great—offering valuable lessons for all companies.
Get Science Lessons by at the best price and quality guaranteed only at Werezi Africa's largest book ecommerce store. The book was published by Harvard Business Review Press and it has pages.
